CORALreef OUTCOMES (Recruiting)
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk
- Medicine
- enlicitide (oraal PCSK9-i)
- Population
- ASCVD
- Phase
- III
- Starting year
- 2022